CTIS2023-508208-40-00进行中(未招募)1 期
Short versus long antiplatelet therapy after TAVI
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Age = 18, •Successful transfemoral TAVI for symptomatic aortic stenosis as defined by VARC-33 oSuccessful access, delivery of the device, and retrieval of the delivery system oCorrect positioning of a single prosthetic heart valve into the proper anatomical location oFreedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access-related, or cardiac structural complication, •Written informed consent, •Social security affiliated, •French speaking, •Male or, post-menopausal -with no menses for 12 months without an alternative medical cause- or permanently sterilized -hystercetomy, bilateral salpingectomy or bilateral oophorectomy- female
排除标准
- •Un-successful TAVI defined by the absence of any of the above-mentioned criteria defining successful TAVI, •Women of childbearing potential: non menopaused -with no menses for 12 months without an alternative medical cause- and not permanently sterilized -hystercetomy, bilateral salpingectomy or bilateral oophorectomy-, •Alternative non-femoral-approach TAVI: apical, direct trans-aortic, subclavian, axillary or carotid approaches, •TAVI for other indications than aortic stenosis (pure aortic regurgitation), •Valve in valve TAVI, •Any indication for long term antiplatelet therapy: (e.g. coronary artery disease, cerebrovascular disease, peripheral arterial disease…) at any time prior to randomization, •Any indication for oral anticoagulation: (e.g. atrial fibrillation, deep vein thrombosis, pulmonary embolism, ventricular thrombus…) at any time prior to randomization, •Patients on long term antiplatelet or anticoagulant therapy prior to TAVI for any other indication than TAVI, •Any contraindication to long term antiplatelet therapy (e.g. allergy or intolerance to aspirin, major bleeding, high bleeding risk, thrombocytopenia < 50 000, major haemostasis disorder…), •Adult with protective measures (tutorship, curatorship)
研究者
相似试验
招募中
3 期
Short Versus Long Antiplatelet Therapy After TAVITranscatheter Aortic Valve ReplacementNCT06518317University Hospital, Caen1,400
招募中
4 期
Impact of continuous antiplatelet therapy versus temporary interruption of antiplatelet therapy on the occurrence of bleeding during colonoscopic polypectomycolonic adenomasOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonCardiovascular - Other cardiovascular diseasesACTRN12616000895482The Alfred992
已完成
不适用
Impact of 1-month Dual Antiplatelet Therapy After Treatment with Drug-Coated Balloon for Femoropopliteal Artery DiseaseArteriosclerosis obliteransJPRN-UMIN000034867Hyogo College of Medicine151
招募中
3 期
To Compare Longterm Single versus Dual Antiplatelet Therapy In Ischemic Stroke due to atherosclerotic narrowing of blood vessel in the brain.CTRI/2022/01/039445Dr Rohit Bhatia
进行中(未招募)
1 期
Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study - ADRIFTMedDRA version: 19.1 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersEUCTR2017-001567-20-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)90
